MedTrace Logo

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

NCT05732662 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-02-17

No results posted yet for this study

Summary

The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.

Conditions

  • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Interventions

RADIATION

SBRT

24-50Gy/8-12.5Gy/3-4f

DRUG

Cadonilimab

10 mg/kg,q3w

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05732662 on ClinicalTrials.gov